Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies

Transaction comes as Trump administration confirms it is exploring cannabis rescheduling, creating unprecedented potential opportunities for international operators like InterCure

InterCure encouraged by recent regulatory momentum and positioned to capitalize on evolving U.S. cannabis landscape
 

NEW YORK & HERZLIYA, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd.(NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced the strategic acquisition of Botanico Ltd., also known as ISHI ("ISHI"), a premium medical cannabis technology and brand company that delivers immediate access to advanced cultivation technologies and established partnerships with leading American cannabis operators. The acquisition comes as the U.S. cannabis market stands at a historic potential inflection point, with the Trump administration reportedly exploring the rescheduling of cannabis from Schedule I to Schedule III1 – a transformative regulatory shift that could unlock unprecedented opportunities for international cannabis companies such as InterCure.

Key Transaction Details

• Transaction Structure: Two-phase acquisition of 100% of ISHI (Botanico Ltd.) with 50% of the equity acquired at the initial closing in consideration for 2,467,055 InterCure ordinary shares. The remaining 50% will be acquired upon the earlier of (i) ISHI achieving positive operating profitability for at least three consecutive months or (ii) 24 months from the initial closing, in consideration for an additional 2,457,206 InterCure ordinary shares.
• Total Consideration: 4,924,261 ordinary shares of InterCure, representing approximately 10% of InterCure's outstanding shares on a fully diluted basis
• Management Integration: ISHI founders Omer Layani (CEO) and Dor Hershkovitz (COO) join InterCure leadership team
• Employee Transition: All existing ISHI stock options convert to InterCure options, maintaining original vesting schedules
• Expected Closing: Q1 2026, subject to regulatory approvals from The Israeli Medical Cannabis Agency, The Israel Securities Authority, and The Tel Aviv Stock Exchange
• Operational Integration: Immediate transfer of exclusive brand partnerships and technology platform upon closing. The acquisition delivers immediate access to ISHI's premium indoor product supply, brand portfolio, technology, and operational systems that will enhance InterCure's supply chain and distribution operations while supporting expansion into international markets where pharmaceutical-grade standards are becoming the global benchmark.